Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Down 83.9% in June

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) saw a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 48,137 shares, a drop of 83.9% from the May 31st total of 298,780 shares. Based on an average trading volume of 825,528 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold”.

Get Daiichi Sankyo alerts:

View Our Latest Report on DSNKY

Daiichi Sankyo Trading Up 0.5%

Daiichi Sankyo stock opened at $15.85 on Friday. Daiichi Sankyo has a 1 year low of $14.98 and a 1 year high of $27.50. The firm’s 50 day moving average price is $16.50 and its 200-day moving average price is $18.57. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.42 and a quick ratio of 1.64. The stock has a market cap of $29.53 billion, a P/E ratio of 16.86, a PEG ratio of 2.72 and a beta of -0.16.

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last issued its earnings results on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The company had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.74 billion. Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. On average, equities analysts predict that Daiichi Sankyo will post 0.98 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.

Featured Articles

• Five stocks we like better than Daiichi Sankyo
• 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
• 3 Waste Stocks Turning AI Investments into Growth
• 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
• 3 ETFs Pairing Market-Beating Returns With High Dividend Yields

Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.